Metastatic Colorectal Cancer (mCRC)NCT07861386
Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases
An observational study of Metastatic Colorectal Cancer (mCRC), run by Brigham and Women's Hospital at 1 site in United States.
Trial summary
This trial emulation study aims to emulate the MAVERICC trial (NCT01374425) using real-world specialty oncology electronic health record data and to investigate the concordance between the trial's original and emulated treatment effect estimates on overall survival (OS). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Colorectal Cancer (mCRC)
- What is being tested?
- FOLFIRI plus bevacizumab and mFOLFOX6 plus bevacizumab
- How many people
- 9,978 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Aug 2026to 20 Oct 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with previously untreated metastatic colorectal cancer who initiated FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line treatment.
Who may be able to join
- Age 18 years or older at first-line study regimen initiation.
- Metastatic colorectal cancer documented in a specialty oncology electronic health record.
- Initiation of FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line systemic treatment for metastatic disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the database.
Who cannot join
- Evidence of brain metastases at or before study regimen initiation.
- Prior systemic treatment for metastatic colorectal cancer.
- Adjuvant chemotherapy within 12 months before study regimen initiation.
- Another primary malignancy within five years before study regimen initiation, except cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.
- Use of an investigational agent within 28 days before study regimen initiation.
- Other anticancer treatment during the treatment assessment window, where ascertainable in the database.
Trial locations and contacts
1 site in 1 country.
United States1 site
Brigham and Women's Hospital
Somerville, Massachusetts, 02145
About this study
Official title: Emulation of the MAVERICC (NCT01374425) Trial Using Specialty Oncology Electronic Health Records Databases
This trial emulation study aims to emulate the MAVERICC trial (NCT01374425) using real-world specialty oncology electronic health record data and to investigate the concordance between the trial's original and emulated treatment effect estimates on overall survival (OS). MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).
Read the detailed description
Randomized controlled trials (RCTs) are generally regarded as the gold-standard of evidence for establishing efficacy of medical products. However, real-world data (RWD) are increasingly used to complement evidence from RCTs. Yet, to have confidence in the accuracy of non-interventional studies medical products and their outcomes in oncology, investigators need to know what questions can be validly answered, with which non-interventional study designs, and which analysis methods are appropriate, given the data that is available. Building on a process from the RCT DUPLICATE initiative, EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) is the trial emulation discussed in this protocol, which is part of the expansion project specific to oncology and aims to emulate 12 randomized oncology RCTs using multiple EHR data sources.
The purpose of this protocol is to describe the emulation of the MAVERICC trial. MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Being tested
- FOLFIRI plus bevacizumab, mFOLFOX6 plus bevacizumab
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FOLFIRI plus bevacizumabDrug
Also called FOLFIRI-BV
Observed initiation of first-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
mFOLFOX6 plus bevacizumabDrug
Also called mFOLFOX6-BV
Observed initiation of first-line mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
| Study group | Role | What they receive |
|---|---|---|
| Initiation of FOLFIRI plus bevacizumab | Not described Receives: Drug: FOLFIRI plus bevacizumab | |
| Initiation of mFOLFOX6 plus bevacizumab | Not described Receives: Drug: mFOLFOX6 plus bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to all-cause mortality (overall survival)
Hazard ratio (95% CI)
Measured: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start20 Aug 2026
- Primary completion20 Oct 2026 (estimated)
- Study completion20 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metastatic Colorectal Cancer (mCRC)Studies of the same condition, open and under way.
- More trials run by Brigham and Women's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 9,978 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Food and Drug Administration (FDA)
- Responsible party
- Principal investigator, Shirley Vichy Wang, Brigham and Women's Hospital
- Investigators
- Shirley V Wang, PhD, ScM, Principal investigator, Brigham and Women's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07861386
- Sponsor's protocol ID
- 2022P002556-ENC-MAVERICC
- Other IDs
- 75F40122C00181
- Status last verified
- Sep 2026
- First submitted
- 29 Sep 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No